| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
47,830,000 |
| Market
Cap: |
12.75(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.298 - $3.49 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile GlycoMimetics is a clinical-stage biotechnology company focused on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a main role. Co. is developing uproleselan, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia, a hematologic cancer, and potentially other hematologic cancers. Co. is also developing a drug candidate, GMI-1359, that simultaneously targets both E-selectin and a chemokine receptor known as CXCR4. Co. has designed an antagonist of E-selectin, GMI-1687, that could be suitable for subcutaneous administration.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
65,403 |
2,581,565 |
| Total Buy Value |
$0 |
$0 |
$90,256 |
$4,837,462 |
| Total People Bought |
0 |
0 |
1 |
9 |
| Total Buy Transactions |
0 |
0 |
2 |
21 |
| Total Shares Sold |
0 |
0 |
3,700 |
4,053,849 |
| Total Sell Value |
$0 |
$0 |
$7,215 |
$12,677,616 |
| Total People Sold |
0 |
0 |
1 |
2 |
| Total Sell Transactions |
0 |
0 |
1 |
6 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sandell Scott D |
10% Owner |
– – • |
2023-01-26 |
4 |
S |
$3.12 |
$9,356,400 |
I/I |
(3,000,000) |
2,237,196 |
|
39% |
|
| Sandell Scott D |
10% Owner |
– – • |
2023-01-25 |
4 |
S |
$3.26 |
$2,128,115 |
I/I |
(652,016) |
3,588,288 |
|
35% |
|
| Sandell Scott D |
10% Owner |
– – • |
2023-01-04 |
4 |
S |
$2.91 |
$296,743 |
I/I |
(101,984) |
3,914,072 |
|
29% |
|
| Sandell Scott D |
10% Owner |
– – • |
2023-01-03 |
4 |
S |
$2.99 |
$522,711 |
I/I |
(174,814) |
3,960,002 |
|
34% |
|
| Sandell Scott D |
10% Owner |
– – • |
2022-12-30 |
4 |
S |
$3.02 |
$366,432 |
I/I |
(121,335) |
4,038,732 |
|
43% |
|
| Rock Edwin |
Chief Medical Officer |
• – – |
2022-12-22 |
4 |
B |
$2.25 |
$247,500 |
D/D |
110,000 |
310,000 |
2.74 |
-35% |
|
| Junius Daniel M |
Director |
– • – |
2022-11-17 |
4 |
B |
$1.87 |
$37,400 |
D/D |
20,000 |
63,250 |
2.39 |
-39% |
|
| Rock Edwin |
Chief Medical Officer |
• – – |
2022-11-15 |
4 |
B |
$1.66 |
$166,000 |
D/D |
100,000 |
200,000 |
2.74 |
-25% |
|
| Rock Edwin |
Chief Medical Officer |
• – – |
2022-11-14 |
4 |
B |
$1.43 |
$143,000 |
D/D |
100,000 |
100,000 |
2.74 |
-3% |
|
| Magnani John L. |
SVP of Research, CSO |
• – – |
2022-11-11 |
4 |
B |
$1.17 |
$52,703 |
D/D |
45,045 |
366,078 |
2.74 |
14% |
|
| Pearson Timothy R |
Director |
– • – |
2022-11-11 |
4 |
B |
$1.29 |
$25,026 |
D/D |
19,400 |
24,650 |
2.39 |
14% |
|
| Hahn Brian M. |
SVP Finance, CFO |
• – – |
2022-11-11 |
4 |
B |
$1.06 |
$21,200 |
D/D |
20,000 |
56,843 |
2.74 |
14% |
|
| Semerjian Harout |
Chief Executive Officer |
• • – |
2022-11-11 |
4 |
B |
$1.29 |
$32,250 |
D/D |
25,000 |
25,000 |
2.81 |
14% |
|
| Girard Armand |
SVP, Chief Business Officer |
• – – |
2022-11-11 |
4 |
B |
$1.05 |
$6,825 |
D/D |
6,500 |
29,161 |
2.74 |
14% |
|
| Girard Armand |
SVP, Chief Business Officer |
• – – |
2022-03-09 |
4 |
S |
$1.09 |
$2,550 |
D/D |
(2,339) |
22,661 |
|
30% |
|
| Hahn Brian M. |
SVP Finance, CFO |
• – – |
2022-03-09 |
4 |
S |
$1.09 |
$3,180 |
D/D |
(2,917) |
36,843 |
|
30% |
|
| Magnani John L. |
SVP of Research, CSO |
• – – |
2022-03-09 |
4 |
S |
$1.09 |
$3,517 |
D/D |
(3,227) |
321,033 |
|
30% |
|
| Andrews Patricia S |
Director |
– • – |
2021-11-16 |
4 |
B |
$2.05 |
$82,000 |
D/D |
40,000 |
45,250 |
2.39 |
-43% |
|
| Pearson Timothy R |
Director |
– • – |
2021-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
5,250 |
5,250 |
|
- |
|
| Goldberg Mark Alan |
Director |
– • – |
2021-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
5,250 |
5,250 |
|
- |
|
| Junius Daniel M |
Director |
– • – |
2021-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
5,250 |
43,250 |
|
- |
|
| Jackson Scott Thomas |
Director |
– • – |
2021-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
5,250 |
5,250 |
|
- |
|
| Koenig Scott |
Director |
– • – |
2021-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
5,250 |
5,250 |
|
- |
|
| Andrews Patricia S |
Director |
– • – |
2021-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
5,250 |
5,250 |
|
- |
|
| Feldman Eric Jay |
Chief Medical OfficerOfficer |
• – – |
2021-03-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
50,498 |
|
-38% |
|
116 Records found
|
|
Page 2 of 5 |
|
|
0.03 (10.54%) 
